Results 191 to 200 of about 73,182 (252)
Regulatory T Cells in Health and Disease
Regulatory T cells (Tregs) arise through distinct developmental pathways and adapt to specialized tissue niches to maintain immune tolerance, barrier integrity, and metabolic homeostasis. In disease, Tregs undergo context‐dependent changes, ranging from functional insufficiency and lineage instability in autoimmune, inflammatory, cardiovascular, and ...
Mingyi Li +4 more
wiley +1 more source
microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer. [PDF]
Biltekin E, Ozpolat B.
europepmc +1 more source
OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1
OTUD1 interacts with AKT and decreases AKT‐mTOR pathway activity, facilitating the translocation of TFEB to the nucleus, thereby triggering autophagy‐dependent degradation of PD‐L1 in lysosomes. . ABSTRACT Upregulation of PD‐L1 on tumor cells is a pivotal aspect of immune evasion, leading to treatment resistance, tumor recurrence, and metastasis ...
Yang Hao +10 more
wiley +1 more source
Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential. [PDF]
Xiang M, Liu S, Xiao D, Tao Y.
europepmc +1 more source
A Pan‐HEpatic single‐cell Atlas of T cells (Pheat) was constructed covering chronic hepatitis, cirrhosis, hepatocellular carcinoma (HCC), and healthy controls. CD8+ exhausted T cells (Tex) and CD4+ regulatory T cells (Treg) were delineated profound through decoding molecular and cellular variance, immune checkpoint networks, pathway analysis, and drug ...
Si‐Yuan Chen +18 more
wiley +1 more source
Bridging BET bromodomain and immune checkpoint inhibitors through generative bioorganic frameworks for next-generation cancer immunotherapy. [PDF]
Diab MK +4 more
europepmc +1 more source
Radionuclide‐conjugated drugs (RDCs) integrate molecular targeting, quantitative imaging, and dosimetry to enable image‐guided precision cancer theranostics. Through coordinated ligand–chelator–radionuclide design, RDCs support patient selection, targeted radiation delivery, response monitoring, and adaptive treatment optimization, providing a ...
Chen Fu +7 more
wiley +1 more source
Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer. [PDF]
Bautista J +5 more
europepmc +1 more source
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu +2 more
wiley +1 more source

